Multicenter Automatic Defibrillator Implantation Trial–Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol
Year: 2017
Type: article
Study design: Study Protocol
Abstract: Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
Source: American Heart Journal
Authors: Valentina Kutyifa, Christopher Beck, Mary W. Brown, David Cannom, James Daubert, Mark Estes, Henry Greenberg, Ilan Goldenberg, Stephen Hammes, David Huang, Helmut Klein, Reinoud Knops, Mikhail Kosiborod, Jeanne Poole, Claudio Schuger, Jagmeet P. Singh, Scott Solomon, David Wilber, Wojciech Zareba, Arthur J. Moss
Institutions: University of Rochester Medicine, University of Rochester, University of California, Los Angeles, Duke University, Tufts Medical Center, Columbia University, Sheba Medical Center, Amsterdam UMC Location University of Amsterdam, Saint Luke's Hospital, University of Washington, Henry Ford Hospital, Massachusetts General Hospital, Brigham and Women's Hospital, Loyola University Medical Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,070
OpenAlex ID: W2611389622